Patheon bolsters regulatory offering through Swiftwater deal

Related tags Pharmacology

Patheon has teamed up with drug development consultant Swiftwater to offer customers advice and guidance on regulatory and compliance issues.

Washington DC, US headquartered Swiftwater will help Patheon’s clients navigate the increasingly choppy regulatory seas, providing advice on drug development, documentation and product submission.

Patheon CEO Wes Wheeler said the partnership provides a useful expansion of the firm’s portfolio, explaining that: “Many of our clients benefit from strategic and tactical assistance with their NDA filings, 505(b) 2 filings, bioequivalence requirements, technical transfers and paediatric line extension strategies​.”

Thomas Fritz, Managing Partner of Swiftwater added that the partnership will cover “the full development spectrum from pre-clinical to regulatory approval, at the same time ensuring tight coordination of manufacture, nonclinical program development and execution, clinical study design and execution, and regulatory documentation​."

Related news

Show more

Related products

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

The Complete Guide to eRegulatory and eSource

The Complete Guide to eRegulatory and eSource

Content provided by Florence Healthcare | 01-Apr-2023 | Insight Guide

Shifting to eRegulatory and eSource workflows is a requirement for clinical trial sites to continue to scale and grow their studies. This guide is designed...

Follow us


View more